Craig-Hallum assumed coverage of DiaMedica Therapeutics with a Buy rating and $8 price target. While DiaMedica’s pivotal acute ischemic stroke trial is far from risk-free, the firm believes shares present a favorable risk-reward and think that the current stock price assumes a less than 10% chance of success, even when assuming further dilution as the company finishes development. This compares to the typical chance CNS drugs progress of Phase 3 to approval of 51%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DMAC:
- DiaMedica Therapeutics says first patient dosed in relaunch of DM199 trial
- Diamedica Therapeutics Updates SEC Filing
- DiaMedica Therapeutics files $100M mixed securities shelf
- DiaMedica Therapeutics price target lowered to $8 from $11 at Craig-Hallum
- DiaMedica Therapeutics price target lowered to $6 from $7 at Oppenheimer